Advertisement

Topics

Scotland backs Pfizer’s Ibrance for breast cancer

06:44 EDT 11 Jul 2019 | pharmaphorum

Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced breast cancer after hormonal therapy. The Scottish Medicines Consortium (SMC) said Ibrance – a CDK4/6 inhibitor – can increase the time befor...

Original Article: Scotland backs Pfizer’s Ibrance for breast cancer

NEXT ARTICLE

More From BioPortfolio on "Scotland backs Pfizer’s Ibrance for breast cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...